Accessibility Menu
Rafarma Pharmaceuticals logo

Rafarma Pharmaceuticals(OTC) RAFA

Market Cap$2.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-99%
5 Year-98%
1 Year-54%
1 Month+15%
$0.03
-8.54%
-0.00Today
Rafarma Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.032026-09-01
Rafarma Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.8%USD 0.042026-08-20
1 month+15.38%USD 0.032026-07-31
3 month-40%USD 0.052026-06-03
Year to date+9.39%USD 0.032025-12-31
1 year-54.2%USD 0.072025-08-29
3 year-88%USD 0.252023-09-01
5 year-97.58%USD 1.242021-09-02
Since inception-98.8%USD 2.502012-10-18

Rafarma Pharmaceuticals Financials at a Glance

Market Cap

$2.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$9.23M

Net Income (TTM)

$363.00K

EPS (TTM)

$0.00

P/E Ratio

7.14

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Price

$0.03

Volume

11,853

Open

$0.02

Previous Close

$0.03

Daily Range

$0.02 - $0.03

52-Week Range

$0.00 - $0.10

Estimated Earnings Date

N/A

RAFA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rafarma Pharmaceuticals

Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise focused on manufacturing and distributing a variety of medicinal products, primarily within the Russian market. The company specializes in generic antibiotics and specialized drugs, including anti-cancer medications and non-beta-lactam antibiotics.

Products and Services
  • Manufactures generic antibiotics and specialized drugs
  • Develops treatments for injuries and ocular inflammatory conditions
  • Collaborates on medical cannabis research for inflammatory bowel disease
Growth Outlook
  • Recent quarterly revenue reached $302,000, indicating stable demand
  • Net income for Q1 2026 was $80,000, showcasing profitability
  • Strong gross profit margin of 42.7% reflects operational efficiency
Financial Highlights
  • Trailing twelve months (TTM) revenue of $8.3 million demonstrates growth potential
  • Current ratio of 1.09 indicates solid short-term financial health
  • Price-to-earnings (P/E) ratio of 11.54 suggests attractive valuation compared to peers
Rafarma Pharmaceuticals, Inc. operates in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic medications. The company has established a strong presence in the Russian market, leveraging its expertise in producing a diverse range of pharmaceutical products. The collaboration with PlantEXT Ltd. for medical cannabis research highlights Rafarma's commitment to innovation and addressing emerging healthcare needs. The growth outlook appears promising, with recent financial performance indicating a stable revenue stream and profitability. The gross profit margin of 42.7% in the latest quarter reflects effective cost management and operational efficiency. Additionally, the current ratio of 1.09 suggests that the company is well-positioned to meet its short-term obligations, further enhancing its financial stability. Investors may find Rafarma Pharmaceuticals, Inc. an intriguing opportunity, given its competitive positioning in the pharmaceutical market and its focus on innovative product development. The company's financial metrics, including a favorable P/E ratio, indicate potential for future growth and value creation.
AI Generated • Sep 5, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Raivo Unt

Website

www.rafarma.com

Headquarters

Sandy, UT 84070, US

RAFA Financials

Key Financial Metrics (TTM)

Gross Margin

8.48%

Operating Margin

5.45%

Net Income Margin

3.93%

Return on Equity

3.48%

Return on Capital

4.65%

Return on Assets

3.02%

Earnings Yield

14.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

93.17M

Volume

11.85K

Avg. Volume

11.17K

Financials (TTM)

Gross Profit

$782.00K

Operating Income

$503.00K

EBITDA

$513.00K

Operating Cash Flow

$725.00K

Capital Expenditure

-$725.00K

Free Cash Flow

$0.00

Cash & ST Invst.

$60.00K

Total Debt

$22.00K

Rafarma Pharmaceuticals Performance Analysis

Rafarma Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 64,314,000-16.9%
20232023-12-31USD 10,135,000-84.2%
20242024-12-31USD 9,078,000-10.4%
20252025-12-31USD 9,177,0001.1%
Rafarma Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-03-31-96.8%
Q32025-12-31N/A
Q42026-03-31-96.3%
Q12026-06-30-1.9%
Rafarma Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.06-57.2%
20232023-12-31USD 0.00-94.5%
20242024-12-31USD 0.00-3.2%
20252025-12-31USD 0.0033.3%
Rafarma Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-03-31-82.4%
Q32025-12-31N/A
Q42026-03-31-35.7%
Q12026-06-30-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$302.00K

-96.5%

Gross Profit

$129.00K

-70.9%

Gross Margin

42.72%

N/A

Market Cap

$2.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.99K

N/A

Employees

700

N/A

Net Income

$80.00K

-45.6%

EBITDA

$88.00K

-60.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$60.00K

-22.1%

Total Debt

$22.00K

N/A

Accounts Receivable

$1.47M

-9.6%

Inventory

$165.00K

+5.8%

Long Term Debt

$22.00K

N/A

Short Term Debt

$0.00

N/A

Return on Assets

3.02%

N/A

Return on Invested Capital

4.81%

N/A

Free Cash Flow

$1.00K

+100.1%

Operating Cash Flow

$2.00K

+100.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
UBQUUbiquitech Software Corp.
$0.00+0.00%
LVVVLiveWire Ergogenics, Inc.
$0.00+0.00%
LMLLFPharmadrug Inc.
$0.01+1.83%
TNRGThunder Energies Corporation
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About RAFA

What is the current price of Rafarma Pharmaceuticals?

Rafarma Pharmaceuticals is trading at $0.03 per share.

What is the 52-week range for Rafarma Pharmaceuticals?

Over the past 52 weeks, Rafarma Pharmaceuticals has traded between $0.00 and $0.10.

How much debt does Rafarma Pharmaceuticals have?

As of the most recent reporting period, Rafarma Pharmaceuticals reported total debt of $22.00K.

How much cash does Rafarma Pharmaceuticals have on hand?

Rafarma Pharmaceuticals reported $60.00K in cash and cash equivalents in its most recent financial results.

What is Rafarma Pharmaceuticals’s dividend yield?

Rafarma Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services